Interest in Integrative Medicine among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study

Integrative Cancer Therapies

Volumn 16, Issue 2, 2017, Pages 165-175

  Hack, Carolin C ^a   Fasching, Peter A ^a,c   Fehm, Tanja ^b   De Waal, Johann ^d   Rezai, Mahdi ^e   Baier, Bernd ^d   Baake, Gerold ^f   Kolberg, Hans Christian ^g   Guggenberger, Martin ^h   Warm, Mathias ^i,j   Harbeck, Nadia ^c,k   Wuerstlein, Rachel ^c,k   Deuker, Jörg Uwe ^l   Dall, Peter ^m   Richter, Barbara ⁿ   Wachsmann, Grischa ^o   Brucker, Cosima ^p   Siebers, Jan W ^q   Fersis, Nikos ^r   Kuhn, Thomas ^s   Wolf, Christopher ^t   Vollert, Hans Walter ^u   Breitbach, Georg Peter ^v   Janni, Wolfgang ^w   Landthaler, Robert ^x   Kohls, Andreas ^y   Rezek, Daniela ^z   Noesslet, Thomas ^aa   Fischer, Gunnar ^ab   Henschen, Stefan ^ac   Praetz, Thomas ^ad   Heyl, Volker ^ae   Kühn, Thorsten ^af   Krauss, Thomas ^ag   Thomssen, Christoph ^ah   Hohn, Andre ^ai   Tesch, Hans ^aj   Mundhenke, Christoph ^ak   Hein, Alexander ^a   Rauh, Claudia ^a   Bayer, Christian M ^a   Jacob, Adib ^al   Schmidt, Katja ^al   Belleville, Erik ^am   Hadji, Peyman ^an   Brucker, Sara Y ^c   Wallwiener, Diethelm ^c   Kümmel, Sherko ^ao   Beckmann, Matthias W ^a   Paepke, Daniela ^ap   more..

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Frauenklinik im Klinikum Dachau   (Germany)

^e Breast Center Düsseldorf Luisenkrankenhaus   (Germany)

^f Onkologische Praxis Pinneberg   (Germany)

^g Marien Hospital Bottrop gGmbH   (Germany)

^h Klinikum Tuttlingen   (Germany)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j Brustzentrum   (Germany)

^k UNIVERSITY OF MUNICH   (Germany)

^l St Vinzenz Hospital   (Germany)

^m Municipal Hospital of Lueneburg   (Germany)

ⁿ Elblandkliniken Radebeul   (Germany)

^o Kreiskrankenhaus Böblingen   (Germany)

^p Universitätsklinik für Frauenheilkunde und Geburtshilfe   (Germany)

^q St Josefsklinik   (Germany)

^r INSTITUTE OF PATHOLOGY   (Germany)

^s Karl Olga Krankenhaus   (Germany)

^t Medizinisches Zentrum Ulm   (Germany)

^u Klinikum Friedrichshafen   (Germany)

^v Abteilung für Urologie   (Germany)

^w UNIVERSITY HOSPITAL ULM   (Germany)

^x Gynäkologische Praxis in der Kreisklinik Krumbach   (Germany)

^y Evangelisches Krankenhaus Ludwigsfelde Teltow   (Germany)

^z MARIEN HOSPITAL WESEL   (Germany)

^aa Kreiskrankenhaus Hameln   (Germany)

^ab Landkreis Mittweida Krankenhaus GGmbH   (Germany)

^ac Johanniter Krankenhaus Genthin Stendal GmbH   (Germany)

^ad CARITAS KRANKENHAUS   (Germany)

^ae Asklepios Paulinen Klinik   (Germany)

^af KLINIKUM CHEMNITZ   (Germany)

^ag Lippe Detmold Hospital   (Germany)

^ah MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^ai Stroke Unit Neurologie   (Germany)

^aj Bethanien Krankenhaus Frankfurt   (Germany)

^ak UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^al NOVARTIS PHARMA GMBH   (Germany)

^am Clin Sol Clinical Research Solutions GmbH   (Germany)

^an KRANKENHAUS NORDWEST   (Germany)

^ao KLINIKEN ESSEN MITTE   (Germany)

^ap TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

aromatase inhibitor; breast cancer; complementary and alternative medicine; information; integrative medicine; letrozole; oncology; therapy management

Indexed keywords

AROMATASE INHIBITOR; HORMONE RECEPTOR; LETROZOLE; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; FITNESS; HORMONAL THERAPY; HUMAN; INTEGRATIVE MEDICINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUTRITIONAL COUNSELING; PATIENT SATISFACTION; POLYPHARMACY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REHABILITATION CARE; TUMOR VOLUME; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECTS; GERMANY; MIDDLE AGED; PROCEDURES;

AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; GERMANY; HUMANS; INTEGRATIVE MEDICINE; MIDDLE AGED; NITRILES; POSTMENOPAUSE; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 85019545302     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735416668575     Document Type: Article

References (53)

1. Kaatsch P, Spix C, Hentschel S, et al. Krebs in Deutschland 2009/2010. Berlin, Germany: Robert Koch-Institut/die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.; 2013.
2. Eisemann N, Waldmann A, Katalinic A,. Epidemiology of breast cancer-current figures and trends. Geburtshilfe Frauenheilkd. 2013; 73: 130-135.
3. Redden MH, Fuhrman GM,. Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Clin North Am. 2013; 93: 493-499.
4. Schmidt M,. Chemotherapy in early breast cancer: when, how and which one? Breast Care (Basel). 2014; 9: 154-160.
5. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice guideline focused update. J Clin Oncol. 2014; 32: 2255-2269.
6. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24: 2206-2223.
7. Penttinen HM, Saarto T, Kellokumpu-Lehtinen P, et al. Quality of life and physical performance and activity of breast cancer patients after adjuvant treatments. Psychooncology. 2011; 20: 1211-1220.
8. Odle TG,. Adverse effects of breast cancer treatment. Radiol Technol. 2014; 85: 297M-319M.
9. Buijs C, de Vries EG, Mourits MJ, Willemse PH,. The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev. 2008; 34: 640-655.
10. Bani HA, Fasching PA, Lux MM, et al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. Patient Educ Couns. 2007; 66: 311-318.
11. Bani MR, Beckmann K, Engel J, et al. Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. Breast. 2008; 17: 640-645.
12. Jud SM, Fasching PA, Maihofner C, et al. Pain perception and detailed visual pain mapping in breast cancer survivors. Breast Cancer Res Treat. 2010; 119: 105-110.
13. Jud SM, Hatko R, Maihofner C, et al. Comprehensive visualization of paresthesia in breast cancer survivors. Arch Gynecol Obstet. 2014; 290: 135-141.
14. Hadji P, Jackisch C, Bolten W, et al. COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol. 2014; 25: 372-377.
15. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M,. How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther. 2012; 11: 187-203.
16. Molassiotis A, Scott JA, Kearney N, et al. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006; 14: 260-267.
17. Gerber B, Scholz C, Reimer T, Briese V, Janni W,. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat. 2006; 95: 199-209.
18. Paul M, Davey B, Senf B, et al. Patients with advanced cancer and their usage of complementary and alternative medicine. J Cancer Res Clin Oncol. 2013; 139: 1515-1522.
19. Tautz E, Momm F, Hasenburg A, Guethlin C,. Use of complementary and alternative medicine in breast cancer patients and their experiences: a cross-sectional study. Eur J Cancer. 2012; 48: 3133-3139.
20. Fasching PA, Thiel F, Nicolaisen-Murmann K, et al. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer. 2007; 15: 1277-1284.
21. Molassiotis A, Browall M, Milovics L, Panteli V, Patiraki E, Fernandez-Ortega P,. Complementary and alternative medicine use in patients with gynecological cancers in Europe. Int J Gynecol Cancer. 2006; 16 (suppl 1): 219-224.
22. Blaes AH, Kreitzer MJ, Torkelson C, Haddad T,. Nonpharmacologic complementary therapies in symptom management for breast cancer survivors. Semin Oncol. 2011; 38: 394-402.
23. Casla S, Hojman P, Marquez-Rodas I, et al. Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. Clin Transl Oncol. 2015; 17: 180-196.
24. Finnegan-John J, Molassiotis A, Richardson A, Ream E,. A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue. Integr Cancer Ther. 2013; 12: 276-290.
25. Mansky PJ, Wallerstedt DB,. Complementary medicine in palliative care and cancer symptom management. Cancer J. 2006; 12: 425-431.
26. Deng G, Cassileth BR,. Integrative oncology: complementary therapies for pain, anxiety, and mood disturbance. CA Cancer J Clin. 2005; 55: 109-116.
27. Shneerson C, Taskila T, Gale N, Greenfield S, Chen YF,. The effect of complementary and alternative medicine on the quality of life of cancer survivors: a systematic review and meta-analyses. Complement Ther Med. 2013; 21: 417-429.
28. Yun YH, Lee MK, Park SM, et al. Effect of complementary and alternative medicine on the survival and health-related quality of life among terminally ill cancer patients: a prospective cohort study. Ann Oncol. 2013; 24: 489-494.
29. Saquib J, Parker BA, Natarajan L, et al. Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer. Complement Ther Med. 2012; 20: 283-290.
30. Hann D, Baker F, Denniston M, Entrekin N,. Long-term breast cancer survivors' use of complementary therapies: perceived impact on recovery and prevention of recurrence. Integr Cancer Ther. 2005; 4: 14-20.
31. Sollner W, Maislinger S, DeVries A, Steixner E, Rumpold G, Lukas P,. Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: a survey. Cancer. 2000; 89: 873-880.
32. Huiart L, Bouhnik AD, Rey D, et al. Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS One. 2013; 8: e81677.
33. Wanchai A, Armer JM, Stewart BR,. Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs. 2010; 14: E45-E55.
34. Huebner J, Rose C, Geissler J, et al. Integrating cancer patients' perspectives into treatment decisions and treatment evaluation using patient-reported outcomes-a concept paper. Eur J Cancer Care (Engl). 2014; 23: 173-179.
35. Huebner J, Muenstedt K, Prott FJ, et al. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care (Basel). 2014; 9: 60-63.
36. Huebner J, Micke O, Muecke R, et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res. 2014; 34: 943-948.
37. Nicolaisen-Murmann K, Thiel F, Mohrmann S, et al. Complementary and alternative medicine in women with gynecological and breast malignancies-a multicenter study exploring prevalence and motivation. Geburtshilfe Frauenheilkd. 2005; 65: 178-185.
38. Koehl B, Muenstedt K, Micke O, et al. Survey of German non-medical practitioners regarding complementary and alternative medicine in oncology. Oncol Res Treat. 2014; 37: 49-53.
39. Consortium of Academic Health Centers for Integrative Medicine. What id integrative medicine. https://www.aihm.org/about/what-is-integrative-medicine. Retrieved 24, 2016.
40. The Bravewell Collaborative. Integrative medicine. http://www.bravewell.org/integrative-medicine. Retrieved 24, 2016. 2016.
41. National Center of Complementary and Alternative Medicine. Complementary, alternative and integrative health. http://nccam.nih.gov/health/whatiscam. 20, 2016.
42. Hack C, Hüttner N, Paepke D, et al. Integrative medicine in gynecologic oncology-possibilities and limits part 1. Geburtshilfe Frauenheilkd. 2013; 73: R65-R78.
43. Fasching PA, Fehm T, Kellner S, et al. Evaluation of therapy management and patient compliance in postmenopausal patients with hormone receptor-positive breast cancer receiving letrozole treatment: The EvaluateTM study. Geburtshilfe Frauenheilkd. 2014; 74: 1137-1143.
44. Beckmann MW, Brucker C, Hanf V, et al. Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. Onkologie. 2011; 34: 362-367.
45. Garland SN, Valentine D, Desai K, et al. Complementary and alternative medicine use and benefit finding among cancer patients. J Altern Complement Med. 2013; 19: 876-881.
46. Truant TL, Porcino AJ, Ross BC, Wong ME, Hilario CT,. Complementary and alternative medicine (CAM) use in advanced cancer: a systematic review. J Support Oncol. 2013; 11: 105-113.
47. Vapiwala N, Mick R, Hampshire MK, Metz JM, DeNittis AS,. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J. 2006; 12: 467-474.
48. Yates JS, Mustian KM, Morrow GR, et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer. 2005; 13: 806-811.
49. Pihlak R, Liivand R, Trelin O, et al. Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling. Eur J Cancer Care (Engl). 2014; 23: 249-254.
50. Despres JP, Lemieux I,. Abdominal obesity and metabolic syndrome. Nature. 2006; 444: 881-887.
51. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008; 29: 777-822.
52. Brauer JA, El Sehamy A, Metz JM, Mao JJ,. Complementary and alternative medicine and supportive care at leading cancer centers: a systematic analysis of websites. J Altern Complement Med. 2010; 16: 183-186.
53. Hack CC, Huttner NB, Fasching PA, Beckmann MW,. Development and validation of a standardized questionnaire and standardized diary for use in integrative medicine consultations in gynecologic oncology. Geburtshilfe Frauenheilkd. 2015; 75: 377-383.